Drug Profile
Research programme: HIV integrase inhibitors - Inhibitex
Alternative Names: INH-001; INH-I001Latest Information Update: 17 Feb 2012
Price :
$50
*
At a glance
- Originator University of Georgia
- Developer Inhibitex
- Class
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended HIV infections
Most Recent Events
- 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
- 12 May 2009 Suspended - Preclinical for HIV infections in USA (PO)
- 19 Sep 2007 Preclinical trials in HIV infections in USA (PO)